Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2C | P18825 | 2/20 | 0.64 |
| ▸ | BACE1 | P56817 | 1/20 | 0.57 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.47 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.45 |
| ▸ | CDC7 | O00311 | 1/20 | 0.44 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.44 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.44 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.44 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | KDM6B | O15054 | 1/20 | 0.44 |
| ▸ | KDM4A | O75164 | 1/20 | 0.44 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.44 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30894547 | 1.00 | ADRA2C (0.64) | ADRA2CBACE1HDAC1HTTSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL3874671 | 0.98 | ADRA2C (0.62) | ADRA2CBACE1HDAC1HTTSMN1; SMN2 | |
| SCHEMBL7164883 | 0.86 | BACE1 (0.56) | ADRA2CBACE1HDAC1KDM4EPOLB | |
| SCHEMBL29922357 | 0.84 | BACE1 (0.65) | BACE1HDAC1HTTKDM4EHDAC3 | |
| SCHEMBL396451 | 0.84 | BACE1 (0.65) | BACE1HDAC1HTTKDM4EHDAC3 | |
| SCHEMBL13879812 | 0.82 | HDAC1 (0.69) | BACE1HDAC1HDAC3HDAC2NCOR2 | |
| SCHEMBL3872334 | 0.81 | LTA4H (0.60) | ADRA2CBACE1HDAC1HTTSMN1; SMN2 | |
| SCHEMBL30894545 | 0.80 | BACE1 (0.47) | ADRA2CBACE1HDAC1KDM4EL3MBTL1 | |
| SCHEMBL16489564 | 0.79 | KDM4C (0.56) | ADRA2CBACE1HTTSMN1; SMN2KCNH3 | |
| SCHEMBL16489591 | 0.79 | KDM4C (0.60) | ADRA2CBACE1HTTSMN1; SMN2KCNH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-62249982-A | — | — | None | — | — | JP | disclosed |
| US-7538115-B2 | Substituted piperidines, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-05-26 | — | — | US | disclosed |
| EP-1487821-B1 | BENZODIAZEPINE-SUBSTITUTED PIPERIDINES FOR UTILIZATION IN THE TREATMENT OF CARDIOVASCULAR DISEASES | BOEHRINGER INGELHEIM PHARMA (DE) | 2007-03-21 | — | — | EP | disclosed |
| US-7026312-B2 | Substituted piperidines, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2006-04-11 | — | — | US | disclosed |
| US-20050215546-A1 | Novel substituted piperidines, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-09-29 | — | — | US | disclosed |
| US-20030236282-A1 | Novel substituted piperidines, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof | BOEHRINGER INGELHEIM PHARMA GMBH & CO. (DE) | 2003-12-25 | — | — | US | disclosed |
| JP-S62249982-A | BENZIMIDAZOLINE DERIVATIVE | KISSEI PHARMACEUT CO LTD | 1987-10-30 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236282-A1 | Novel substituted piperidines, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof | P2RX5, CALCRL, ADRA1D | ADRA2C 19/4885BACE1 276/4885HDAC1 2398/4885 |
| US-20050215546-A1 | Novel substituted piperidines, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof | P2RX3, P2RX5, P2RX2 | ADRA2C 35/4885BACE1 348/4885HDAC1 2554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.